{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:11:23Z","timestamp":1788307883386,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.cpcardiol.2023.101667","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T07:04:37Z","timestamp":1677135877000},"page":"101667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Real-World Efficacy of Tafamidis in Patients With Transthyretin Amyloidosis and Heart Failure"],"prefix":"10.1016","volume":"48","author":[{"given":"Ahmed","family":"Ghoneem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0750-1038","authenticated-orcid":false,"given":"Ammar W.","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanth","family":"Khadke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Trachtenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Wechalekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne J.","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"Nohria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lenihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0296-6864","authenticated-orcid":false,"given":"Sarju","family":"Ganatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourbha S.","family":"Dani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2023.101667_bib0001","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0002","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jaccao.2021.06.006","article-title":"ATTR amyloidosis: current and emerging management strategies: JACC: cardiooncology state-of-the-art review","volume":"3","author":"Griffin","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0003","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0004","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0005","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","article-title":"Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis","volume":"77","author":"Nitsche","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0006","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jamacardio.2022.1781","article-title":"A simple score to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"7","author":"Davies","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0007","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","article-title":"Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis","volume":"5","author":"Coelho","year":"2016","journal-title":"Neurol Ther"},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0009","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J of Med"},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0011","unstructured":"FDA. FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis; 2021 [Accessed May 12, 2022]; Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatments-heart-disease-caused-serious-rare-disease-transthyretinmediated."},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0012","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jaccao.2021.08.007","article-title":"Effect of tafamidis on serum transthyretin levels in non-trial patients with transthyretin amyloid cardiomyopathy","volume":"3","author":"Falk","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0013","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/ehjci\/jeac049","article-title":"Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis","volume":"23","author":"Giblin","year":"2022","journal-title":"Eur Heart J - Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(22)01297-9","article-title":"Tafamidis effectiveness in wild-type transthyretin cardiac amyloidosis by mayo staging","volume":"79","author":"Amaka","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0015","doi-asserted-by":"crossref","DOI":"10.1161\/circ.144.suppl_1.12093","article-title":"Abstract 12093: Tafamidis use and new onset atrial fibrillation in patients with cardiac amyloidosis","volume":"144","author":"Sweat","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0016","first-page":"767","article-title":"Cardiac imaging in tafamidis-treatment patients with transthyretin amyloid cardiomyopathy","volume":"42","author":"Rettl","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cpcardiol.2022.101358","article-title":"Impact of tafamidis on survival in a real-world community-based cohort","volume":"47","author":"Hussain","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0018","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/ejhf.2028","article-title":"Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis","volume":"23","author":"B\u00e9zard","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0019","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamacardio.2020.1738","article-title":"Initial experience prescribing commercial tafamidis, the most expensive cardiac medication in history","volume":"5","author":"Masri","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0020","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0021","first-page":"442","article-title":"Prognosis of transthyretin cardiac amyloidosis without heart failure symptoms","volume":"4","author":"Gonzalez-Lopez","year":"2022","journal-title":"JACC: CardioOncol"},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0022","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.amjcard.2021.02.035","article-title":"Causes of cardiovascular hospitalization and death in patients with transthyretin amyloid cardiomyopathy (from the tafamidis in transthyretin cardiomyopathy clinical trial [ATTR-ACT])","volume":"148","author":"Miller","year":"2021","journal-title":"The Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0023","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamacardio.2019.5233","article-title":"Tafamidis-a pricey therapy for a not-so-rare condition","volume":"5","author":"Gurwitz","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0024","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2147\/PPA.S352332","article-title":"Baseline characteristics and secondary medication adherence patterns among patients receiving tafamidis prescriptions: a retrospective analysis using a national specialty pharmacy dispensing database","volume":"16","author":"Roy","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.cpcardiol.2023.101667_bib0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tcm.2017.07.004","article-title":"Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment","volume":"28","author":"Siddiqi","year":"2018","journal-title":"Trends Cardiovasc Med"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623000841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623000841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T11:04:56Z","timestamp":1729076696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280623000841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0146280623000841"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101667","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Efficacy of Tafamidis in Patients With Transthyretin Amyloidosis and Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101667","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101667"}}